|Day Low/High||36.96 / 37.44|
|52 Wk Low/High||33.97 / 46.47|
Breadth leaked, new lows grew and the McClellan Summation Index rolled over a week ago and shows no sign or recapturing the uptrend.
HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Mylan N.
Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic arthritis (JIA) will be presented for the first time during a...
Not intended for UK-based media
UBS lowers its price target on Pfizer to $37 a share and maintains its neutral rating on the stock.
The company generates increased sales from its existing suite of generic drugs as well as some new product launches.
Strong demand for its lineup of generic drugs and more to come from additional upcoming launches as it moves toward closing its deal with Pfizer's PFE Upjohn business all helped boost third-quarter sales and earnings for Mylan.
Jim Cramer says not having enough time, and having too much government regulation, have more impact on the future revenue streams of companies than does the Federal Reserve.
Pfizer's earnings pop could lead the way to a change in trend.
A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #19 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #285 spot.
These stocks are priced for total imperfection. That's just what you want.
U.S. stock futures are mixed as Wall Street awaits an expected rate cut - the third this year - from the Federal Reserve on Wednesday and earnings from Apple; Facebook, General Electric, Starbucks and Twilio also report earnings Wednesday; Fiat Chrysler and Peugeot owner PSA confirm they are in merger talks.
Stocks finish lower Tuesday, even though the S&P 500 sets an intraday record high.
Pfizer posted stronger-than-expected third quarter earnings Tuesday, and boosted its full-year profit guidance, sending shares higher in pre-market trading.
Wall Street futures eased from record highs Tuesday, while global stocks traded mixed amid renewed optimism on U.S.-China trade talks and the expectation of near-term rate support from the Federal Reserve.
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
U.S. stock futures are mixed Tuesday amid renewed optimism on U.S.-China trade talks and the expectation of near-term rate support from the Federal Reserve; the U.S. central bank begins a two-day meeting Tuesday and is expected Wednesday to announce it has cut rates for third third time in 2019; Alphabet falls after earnings miss analysts' expectations.
Pfizer Inc. (NYSE:PFE) reported financial results for third-quarter 2019 and updated certain components of its 2019 financial guidance.
Several times we’ve seen value outperform growth over the years and it has rarely continued longer than a few months.
Jim Cramer explains the unexpected: quarterly results are 'not as bad as feared' -- NABAF. It's boosting stocks that, based on the headlines, should really just crumple.
LOS ANGELES, Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc.
Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Akcea shares soar after the company announces a licensing agreement with Pfizer for its treatment for people with certain cardiovascular and metabolic diseases.
Stocks finish higher after falling earlier in the session following a weak reading on U.S. services sector activity.
Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI ® (encorafenib), MEKTOVI ® (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced...
Pfizer shares edged higher Friday after the company posted promising results from trials of a drug it's developing to treat patients with moderate-to-severe eczema.
Pfizer Inc. and LabCentral announced that Pfizer has selected Neutrolis and Mediar Therapeutics are the winners of this year's Pfizer Golden Ticket Program.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.